Skip to content

RLAY

Relay Therapeutics, Inc.

Key figures

MetricLatest5-year CAGR
Revenue$10M−28.6%
Operating income−$320M—
Net income−$294M—
EPS−$1.51—
Free cash flow−$236M2025—